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Abstract
Background: Inhalation therapy is a cornerstone of treating patients with chronic obstructive pulmonary disease
(COPD). Inhaler types and through-device inhalation parameters influence airway drug delivery. We aimed to
measure the repeatability of inhalation performance through four different commercially available inhalers.
Methods: We recruited control subjects (n¼ 22) and patients with stable COPD (S-COPD, n¼ 16) and during
an acute exacerbation (AE-COPD, n¼ 15). Standard spirometry was followed by through-device inhalation
maneuvers using Ellipta, Evohaler, Respimat, and Genuair. Through-device inspiratory vital capacity
(IVCd) and peak inspiratory flow (PIFd), as well as inhalation time (tin) and breath hold time (tbh), were recorded
and all measurements were repeated in a random manner.
Results: There was no difference in forced expiratory volume in 1 second (FEV1) between patients (S-COPD:
39 – 5 vs. AE-COPD: 32% – 5% predicted, p > 0.05). In controls, the IVCd was significantly reduced by all four
devices in comparison with the slight reduction seen in COPD patients. In all subjects, PIF was lowered when
inhaling through the devices in order of decreasing magnitude in PIFd: Evohaler, Respimat, Ellipta, and
Genuair. The Bland-Altman analysis showed a highly variable coefficient of repeatability for IVCd and PIFd
through the different inhalers for all COPD patients. Based on the intermeasurement differences in patients,
Respimat and Genuair showed the highest repeatability for IVCd, while Genuair and Ellipta performed superior
with regard to PIFd.
Conclusions: Our study is the first to compare repeatability of inhalation performances through different
inhalers in COPD patients, showing great individual differences for parameters influencing lung deposition of
inhaled medication from a given device. Our data provide new insight into the characterization of inhaler use by
patients with COPD, and might aid the selection of the most appropriate devices to ensure the adequate and
consistent delivery of inhaled drugs.
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Introduction
Chronic obstructive pulmonary disease (COPD) isassociated with the progressive decline of lung function.
Acute exacerbation (AE) may be triggered by a viral/bacte-
rial infection or environmental pollutants. COPD AE can last
several days and it is associated with worsening of respiratory
symptoms, necessitating the administration of additional
therapy.(1,2)
Inhalation therapy is the cornerstone of COPD treatment
in stable state and during an AE. Long-acting beta2-agonists
(LABA) and long-acting muscarinic antagonist (LAMA)
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drugs can relieve symptoms and they are recommended as
first-line treatment for COPD. Patients experiencing an in-
creased number of AEs may have benefit from the addition
of inhaled corticosteroids (ICS).(1,3,4)
There are three basic types of commercially available
inhalation devices used for pulmonary drug delivery in pa-
tients with COPD. Pressurized metered-dose inhalers
(pMDIs) contain a liquid medication, which is delivered as
an aerosol spray. The adequate use of pMDIs can be chal-
lenging to patients as it requires the harmonization of the
timing of device actuation and aerosol inhalation with the
correct inspiratory flow.(5) Dry powder inhalers (DPIs) re-
lease a dose of dry powder, which patients have to inhale
rapidly and steadily. Once the powder is loaded in the de-
vice, the flow generated by the patient during inhalation is
responsible for the drug release.(5,6) Furthermore, the soft-
mist inhaler (SMI) provides a premeasured amount of
medicine in a slow-moving mist, reducing the need of co-
ordination between inhalation and inhaler actuation.(7)
The main goal of inhalation therapy is to deliver the right
amount of the right drug to the right place of action within
the airways.(8) It has been shown with modeling studies that
inspiratory vital capacity (IVC), peak inspiratory flow (PIF),
breath hold (tbh), and the time for inhalation (tin) and ex-
halation during device use influence pulmonary drug depo-
sition.(9–11) Furthermore, individual patient characteristics,
including the anatomy of the mouth and upper and lower
airways, also affect drug delivery.(12) In COPD, the actual
physical condition of the patient such as the strength of
inspiratory muscles and the severity of the disease can also
influence the inspiratory maneuver during device use.(13)
The ease of use and patient preference are the driving
factors when selecting an inhaler, but disease severity and
symptom burden can also influence inhalation performance
via inhalers.(14) A good repeatability of inhalation perfor-
mance through a given device is a prerequisite for consistent
delivery of inhaled medications to the airways and for ef-
fective inhalation therapy.(15) Previous studies examined
lung deposition of drug particles inhaled through different
devices,(12,16,17) but data on repeatability of inhalation per-
formance through different inhalers in patients with COPD
are lacking. Therefore, we aimed to test the repeatability of
inhalation performances in control subjects and patients
with stable COPD (S-COPD) and exacerbated COPD, using
four commercially available inhalers.
Materials and Methods
Subjects and study design
Patients with S-COPD (n = 16) were recruited during
regular outpatient visits, patients with exacerbated COPD
(AE-COPD, n = 15) were included <72 hours after hospital
admission due to an acute severe relapse. Patients had been
previously diagnosed with COPD by a respiratory specialist
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) as post-bronchodilator forced expi-
ratory volume in 1 second (FEV1)/FVC <0.70.(1) Therapy
was decided by the treating physician, but all patients were
treated with systemic steroids. Control volunteers (Control,
n = 22) did not have a chronic respiratory disease and were
recruited from employees of the department. Individuals in
the S-COPD and Control groups with acute respiratory tract
infections within 2 weeks and AE-COPD group who suf-
fered from pneumonia or needed noninvasive ventilation
were excluded. Subjects were recruited between April and
December 2015 at the Department of Pulmonology, Sem-
melweis University, Budapest, Hungary.
All procedures were performed in accordance with the 1964
Helsinki Declaration and its later amendments or comparable
ethical standards. All subjects were informed about the meth-
ods and aims of the measurements and signed the informed
consent form. The study was approved by the Ethics Com-
mittee of the Semmelweis University (TUKEB 239/2015).
Study design
The subjects attended a single visit. All patients performed
standard lung function tests, which were followed by the in-
halation maneuvers using at least three different inhalers after
a minimum of a 30-minute break. Subjects filled out disease-
specific and generic quality-of-life questionnaires.
Lung function measurements
Using an electronic spirometer and body plethysmogra-
phy (PDD-301/s; Piston, Budapest, Hungary), lung function
measurements were performed according to the American
Thoracic Society and European Respiratory Society guide-
lines.(18) Pulmonary function variables were expressed as
the percentage of predicted values. None of the records was
post-bronchodilator measurements.
Inhalation maneuvers through different inhalers
Four commercially available inhalers were used in our study:
two DPIs (Ellipta and Genuair), one pMDI (Evohaler), and
one SMI (Respimat). Inhalers with active substances were not
applied during the study.
For through-device lung function testing, an electronic
spirometer was used (PDD-301/sh; Piston), which has built-in
ambient temperature, pressure, and humidity sensors for the
fully automatic BTPS (body temperature, pressure, water
vapor saturated) correction. It is equipped with a PinkFlow
flowmeter (PPF-18; Piston), which measures flow based on
the principle of a symmetric and averaging Pitot tube. The
flowmeter was attached to a plastic piece connecting the in-
haler under testing (Fig. 1). Initially, eight commercially
available devices were tested with a 3-L calibration pump at
30-60-90 L/min flow to investigate if our setup could accu-
rately measure through-device flow rate. From the measured
flow rate, volume was calculated. Only the four devices used
in our study fulfilled the criteria for reliable flow volume
measurement in our setup. The connecting piece was used to
prevent an air leak and subsequent changes of measured
parameters. The metal ring with a rubber overlay was at-
tached to the different mouthpieces of the individual inhalers.
All measurements were performed through a bacterial filter.
Subjects were instructed for 5–10 minutes only before the
measurements to explain and correct inhalation maneuvers
as recommended by the manufacturers of each device. They
could ask questions before measurements, but they were not
allowed to practice inhalation maneuvers. Steps of the in-
halation maneuver were as follows: (1) preparation of the
device; (2) long exhalation; (3) attachment of the inhaler to
the flexible connecting piece; (4) deep inhalation through



























































the inhaler to total lung capacity, with optimal actuation of
pMDI and SMI by the examiner and simultaneous recording
of the prespecified parameters; (5) breath-holding for 10
seconds (when possible) while the inhaler device was de-
tached from the connecting piece; and (6) long exhalation.
Through-device inspiratory vital capacity (IVCd) and peak
inspiratory flow (PIFd) were recorded. In addition, tin and tbh
were also noted. Measurements for all four devices were
performed first in a random manner followed by a different
second sequence in all patients and controls, including a
total of six-eight recordings/subject with at least a 5-minute
break between maneuvers.
Control subjects had never used an inhaler before the
study, but all patients were on inhaled medication, but the
types of their actual regular inhalers were not recorded.
Assessment of symptoms and quality of life
Subjects filled out the Modified Medical Research
Council (mMRC) and the Hungarian version of the COPD
Assessment Test (CAT).(19,20) Furthermore, the visual ana-
log scale (VAS) was used, which is scaled from 0 to 10, to
measure the general health condition of the participants.
A score of 0 reflected no health problems, while a poor
condition was represented by a score of 10.(21)
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software 5 (GraphPad Software, La Jolla, CA) and SPSS
Statistics V22 (International Business Machines Corpora-
tion, NY). The results are expressed as the mean – standard
error of the mean or median (interquartile range). One-way
analysis of variance followed by Bonferroni’s multiple
comparison test, or Kruskal-Wallis test with Dunn’s multi-
ple comparison test was used as appropriate. Repeatability
of measurements was assessed by the Bland-Altman test.(22)
Results were considered to be statistically significant when
the p-value was less than 0.05 ( p < 0.05).
Results
Clinical characteristics of participants
Characteristics of patient groups and control volunteers are
summarized in Table 1. COPD patients significantly differed
from the control group with regard to age, current smoking
habits, and cumulative smoking history. Patients with AE
were slightly younger and had a higher proportion of current
smokers but had less pack-years than S-COPD group patients.
All patients in the AE-COPD group were considered GOLD
D patients as all needed hospitalization due to the relapse, and
no previous category from their stable state was available.
COPD patients had a high number of comorbidities with a
FIG. 1. Measurement configuration attached to Genuair.
(A) Bacterial filter, (B) flowmeter, (C) metal ring with
rubber overlay, (D) inhaler device, (E) spirometer. Color
images are available online.
Table 1. Clinical Characteristics of Controls
and Patients
Control S-COPD AE-COPD
(n = 22) (n = 16) (n = 15)
Female/male 14/8 10/6 11/4
Age (years) 44 – 3 66 – 2* 59 – 2*
BMI (kg/m2) 24.9 – 0.8 25 – 1.2 25.7 – 1.8
Smoking habit, n (%)a
Current smoker 11 (50) 5 (31.25) 10 (67)
Former smoker 1 (4.5) 8 (50) 5 (33)
Never smoker 10 (45.5) 3 (18.75) 0 (0)
Pack-year 18 – 4 50 – 6* 36 – 3*
GOLD category 2017, n (%)
A NA 2 (12.5) 0 (0)
B NA 2 (12.5) 0 (0)
C NA 5 (31) 0 (0)
D NA 7 (44) 15 (100)
Quality of life
mMRC 0 (0–0)1 2 (1–2)2* 4 (3–4)*
CAT 3 (1–7) 9 (7–22)2* 26 (15–31)*
VAS 1 (0–3)3 5 (4–5)2* 7 (5–10)4*
Comorbidities, n (%)
Osteoporosis 1 (6) 4 (7)
Diabetes mellitus 1 (6) 3 (2)
Hypertension 4 (25) 2 (13)
Atherosclerosis 0 (0) 5 (33)**
Myocardial infarct 0 (0) 2 (13)
Cerebral stroke 0 (0) 4 (27)**
Maintenance COPD therapy, n (%)
ICS NA 12 (75) 14 (93)
LABA NA 15 (94) 15 (100)
LAMA NA 15 (94) 15 (100)
Theophylline NA 4 (25) 7 (47)
*p < 0.05 versus Control, **p < 0.05 versus S-COPD.
aChi-square test: p < 0.01.
1n = 21; 2n = 12; 3n = 20; 4n = 14.
AE-COPD, patients with exacerbated chronic obstructive pulmo-
nary disease; BMI, body mass index; CAT, chronic obstructive
pulmonary disease Assessment Test; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid;
LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic
antagonist; mMRC, modified Medical Research Council; NA, not
applicable; S-COPD, patients with stable chronic obstructive
pulmonary disease; VAS, visual analog scale.



























































significantly higher number of vascular comorbidities in AE-
COPD. Patients with exacerbation were more symptomatic
with respect to mMRC, CAT, and VAS scores. The mainte-
nance inhalation therapy was similar between patient groups,
most patients being on triple therapy.
Lung function results
Lung function parameters revealed similar severe airflow
obstruction and lung hyperinflation in both COPD groups,
while normal lung function parameters were noted in the
Control group (Table 2).
Through-device inhalation parameters
using different inhalers
IVCd, PIFd, tin, and tbh were tested for all four devices
(Table 3). IVCd was lower for all devices in controls,
while only a slight decrease was noted in both COPD
groups. In Controls and AE-COPD, PIFd was signifi-
cantly lower compared with PIF during spirometry for all
devices. In S-COPD, PIFd was only significantly de-
creased during inhalation through Genuair. IVCd and
PIFd did not differ significantly for the individual devices
between COPD groups. Inhalation time (tin) was in average
between 2 and 3 seconds except for Genuair in Control and
AE-COPD patients. Mean tbh was above 10 seconds in
Controls and S-COPD, and slightly below the target in AE-
COPD patients.
Repeatability of through-device inhalation parameters
The Bland-Altman analysis was used to define the vari-
ability of the inhalation maneuver parameters through a
given device. Due to the limited number of patients in both
groups, data from COPD patients with measurements in all
devices (S-COPD and AE-COPD) were merged (All-COPD
group, n = 20). Significant individual differences were
present in all tested devices regarding PIFd and IVCd
(Figs. 2–5). The X-axis represents the mean of the two mea-
surements for IVCd and PIFd, while the Y-axis shows the
difference of the repeated measurements (first measurement–
second measurement).
Table 2. Lung Function Values
Control S-COPD AE-COPD
(n = 22) (n = 16) (n = 15)
FVC, % predicted 100 – 3 75 – 6* 63 – 6*
FEV1, % predicted 95 – 2 39 – 5* 32 – 4*
FEV1/FVC, % 80 – 2 43 – 3* 46 – 3*
PEF, % predicted 84 – 7 39 – 4* 32 – 2*
FEF25%–75%, %
predicted
78 – 5 16 – 3* 16 – 2*
PIF, L/s 4.8 – 0.4 2.5 – 0.2* 2.5 – 0.3*
IVC, % predicted 98 – 2 70 – 6* 64 – 5*
TLC, % predicted 93 – 2 104 – 6 113 – 8*
TGV, % predicted 119 – 5 168 – 12* 193 – 15*
RV, % predicted 83 – 6 152 – 17* 192 – 19*
RV/TLC 0.28 – 0.02 0.56 – 0.04* 0.66 – 0.04*
Raw, % predicted 108 – 6 295 – 3* 297 – 31 *
*p < 0.05 versus Control. FEF25%–75%, forced expiratory flow at
25%–75% of the pulmonary volume.
FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; IVC, inspiratory vital capacity; PEF, peak expiratory flow;
PIF, peak inspiratory flow; Raw, airway resistance; RV, residual
volume; TGV, thoracic gas volume; TLC, total lung capacity.
Table 3. Spirometric and Inhalation Parameters Measured Through the Different Inhalers
Control group (n = 22)
Spirometry IVC (L) 3.90 – 1.06
Spirometry PIF (L/s) 4.80 – 1.61
Ellipta Evohaler Respimat Genuair
IVCd (L) 3.41 – 0.78 3.30 – 0.88 3.58 – 0.85 3.21 – 0.91
PIFd (L/s) 1.70 – 0.49* 2.43 – 0.97* 2.02 – 0.67* 1.11 – 0.38*
tin (s) 2.94 – 1.05 2.47 – 1.00 2.70 – 1.11 4.21 – 1.50
tbh (s) 10.04 – 0.72 9.96 – 0.53 10.06 – 0.78 10.21 – 0.78
S-COPD group (n = 16)
Spirometry IVC (L) 2.20 – 0.85**
Spirometry PIF (L/s) 2.50 – 0.77**
Ellipta Evohaler Respimat Genuair
IVCd (L) 2.06 – 0.73 2.12 – 0.68 2.18 – 0.81 1.76 – 0.59
PIFd (L/s) 1.35 – 0.52 1.80 – 0.64 1.53 – 0.60 0.92 – 0.26*
tin (s) 2.43 – 0.89 2.36 – 1.02 2.49 – 1.02 2.88 – 0.33**,***
tbh (s) 10.35 – 0.64 10.32 – 0.51 10.49 – 0.75 10.24 – 0.82
AE-COPD group (n = 15)
Spirometry IVC (L) 2.12 – 0.90**
Spirometry PIF (L/s) 2.51 – 1.15**
Ellipta Evohaler Respimat Genuair
IVCd (L) 2.09 – 0.98 2.00 – 0.93 2.15 – 0.94 1.99 – 1.11
PIFd (L/s) 1.17 – 0.37* 1.68 – 0.47* 1.39 – 0.43* 0.78 – 0.24*
tin (s) 2.81 – 0.99 2.31 – 0.99 2.55 – 0.96 3.46 – 1.09
tbh (s) 9.52 – 0.95 9.67 – 0.59 9.50 – 1.35 9.88 – 0.95
*p < 0.05 versus values obtained by standard spirometry; **p < 0.05 versus Control group; ***p < 0.05 versus AE-COPD.
IVCd, through-device inspiratory vital capacity; PIFd, through-device peak inspiratory flow; tbh, breath hold time; tin, inhalation time.



























































We also calculated the bias (difference between the
X-axis and the average mean of the two measurements for
all subjects) for PIFd and IVCd in Control and All-COPD
groups for each device. It shows how similar these param-
eters were between the two measurements, that is, deviation
from zero (one-sample t-test; Table 4). We found that PIFd
was significantly higher during the second measurement in
controls inhaling through the Evohaler and Respimat, and
there was a trend for higher values for the second maneuver
with the Genuair. Furthermore, we found a trend for higher
first IVCd through the Genuair in controls. Interestingly,
there was only a tendency for higher PIFd for Genuair
during the second measurement in patients, but no signifi-
cant bias in PIFd or IVCd was noted for any inhaler in
COPD.
The 95% limits of agreement and the coefficients of re-
peatability (CR) of IVCd and PIFd through the different
inhalers were high and variable in both controls and patients
(Table 4). It is important to highlight that low CR represent
better repeatability. Of note, the CR in COPD patients for
IVCd were the largest using Ellipta followed by Respimat.
For PIFd, CR were largest in Respimat, followed by Evo-
haler in the All-COPD group.
Ranking of inhalers based on the differences
between inspiratory parameters
We also ranked the four inhalers based on the differences
between the two measurements of PIFd and IVCd (Fig. 6).
This figure highlights the inhalers with the smallest differ-
ence (given Rank 1) in parameters between the two inspi-
ratory maneuvers. Similarly to the findings based on the CR
values in patients with COPD, Respimat and Genuair pro-
duced the smallest intermeasurement differences for IVC,
while Ellipta and Genuair showed the lowest variability for
PIF measurements.
Discussion
Our work is the first to compare the profiles of maneuver
repeatability through four different commercially available
inhalers in COPD patients during stable states and exacer-
bations. As the action of inhaled medication is highly
dependent on proper lung deposition of the drugs, in-
traindividual variability in inhalation maneuvers can lead to
inconsistent pulmonary drug delivery and consequently to
varying degrees of bronchodilation.(12,17)
FIG. 2. Bland-Altman analysis for Ellipta. The X-axis represents the mean of the two measurements for IVCd and
PIFd, while the Y-axis shows the difference of the repeated measurements (first measurement–second measurement).
Each dot represents a person. The dashed line shows the average of the difference for all subjects. IVCd, through-device
inspiratory vital capacity; LoA, Bland-Altman 95% limits of agreement; Meas, measurement; PIFd, through-device peak
inspiratory flow.



























































Adherence to inhaled medications in patients with ob-
structive airway diseases is poor, and inhalation technique
errors have remained frequent over the past 40 years.(23,24)
International recommendations also emphasize the impor-
tance of regular inhaler training in asthma and COPD.(1,25)
Patients require detailed training from well-educated re-
spiratory specialists.(1,26,27) Low adherence to COPD med-
ications is a known important fact and one potential reason
of the daily symptom variability of the disease.(23,28) In
addition, patients’ preferences for individual devices might
vary.(29)
Individual differences of inhalation breath profiles are
generally used to model inhaler performance.(12,30) The
most important breath profile parameters influencing pul-
monary drug deposition include IVCd, PIFd, and tin.
(17,31)
Inhalation parameters have an impact on fine-particle frac-
tion, mass median aerodynamic diameter (MMAD), as well
as on emitted dose, especially in DPIs.(17,31) MMAD can be
determined by measurements with a cascade impactor at
different flow rates and is highly influenced by PIF. Dif-
ferences between interinhalation PIFd in a given patient
result in altered MMAD using DPIs, as well as differences
in deposition pattern and subsequent alteration of thera-
peutic response.(31) Tbh is crucial for small-particle deposi-
tion in the lungs. However, in this highly controlled setting
directed by the examiner, no clinically meaningful differ-
ence was noted.
A former study by Feldman et al. confirmed in a
crossover setting differences in lung function improve-
ment using the LABA-LAMA combination from Ellipta
compared with Respimat in COPD patients, emphasizing
individual response to different inhaled therapies in a
particular patient.(32) To assess variability between the
repeated measurements, we also analyzed data using the
Bland-Altman plot. Significant individual differences
were present in all tested devices in Controls and All-
COPD patients. We found a significant difference for PIFd
through Evohaler and Respimat in the Control group,
which can be related to the limited experience of inhaler
use and the good inspiratory muscle function of these
volunteers. Notably, despite the high through-device var-
iability of PIFd and IVCd in COPD as shown by the high
CR values, the biases between the two measurements were
not statistically significant in COPD. This might be ex-
plained by the previous experience of patients with in-
haled therapy.
FIG. 3. Bland-Altman analysis for Evohaler. The X-axis represents the mean of the two measurements for IVCd and
PIFd, while the Y-axis shows the difference of the repeated measurements (first measurement–second measurement). Each
dot represents a person. The dashed line shows the average of the difference for all subjects.



























































According to our and previous data,(34) intrasubject re-
peatability in the breath profile is an important factor for
therapeutic success. However, lung deposition might differ
using different inhalers, drug formulations, and the quality
of the produced aerosol as well as its sensitivity to breath
profile.(5,8,33–36) In addition, variabilities between batches,
inhaler types, and doses are also important quality attributes
to inhaler performance. Our study focused on one possible
influencing factor: the repeatability of inhalation maneuvers.
We are aware of the limitations of this study; however, this
is the first investigation recording at least two consecutive
maneuvers using four different inhalers in a COPD patient
or healthy volunteer.
In COPD patients, meaningful individual differences for
all inhalers were noted without any specific change at-
tributable to disease severity. Examining the through-
device measurements in COPD patients, it can be observed
that the repeatability of IVCd and PIFd results in a different
sequence of devices in each patient (Fig. 6). IVCd differ-
ence was the smallest in COPD patients using Respimat
and Genuair. However, in some patients, these only ranked
at the third and fourth place, showing the individual, not
predictable, sequence of inhalers. For PIFd, Genuair and
Ellipta reached the best rankings, again the individual
ranking of inhalers presented marked differences. These
data support the clinical observation and the recommen-
dation of the GOLD document for switching the inhaler
device or molecules within the same class when therapy is
considered ineffective.(1) However, no suggestion is given
regarding which other device or molecules should be
prescribed.
AE of COPD can last several days, and the acute wors-
ening of symptoms necessitates additional therapy. Im-
portantly, AEs are more common in patients with more
critical inhaler handling errors.(27) It is difficult to assess
though, if previous maintenance medication was properly
used in our patients. The majority of patients in our AE
study population used triple therapy (ICS, LABA, and
LAMA) and theophylline. However, despite high treatment
intensity, most patients were symptomatic. Symptom relief
is the most important treatment result from a patient’s per-
spective and a decrease in symptoms can decrease health
care utilization.(37) In the exacerbating symptomatic patient
group on triple therapy, there is no real possibility to further
increase the intensity of inhaled therapy, but an optimal
choice from the available inhalation devices can be offered.
As changes of devices may decrease adherence, it would be
useful to measure upfront which inhaler is best suited for a
FIG. 4. Bland-Altman analysis for Respimat. The X-axis represents the mean of the two measurements for IVCd and
PIFd, while the Y-axis shows the difference of the repeated measurements (first measurement–second measurement). Each
dot represents a person. The dashed line shows the average of the difference for all subjects.



























































given patient.(32,38,39) This is further emphasized by the
measurements performed in healthy volunteers, where the
correlation of inhalation parameters was less optimal, es-
pecially using inhalers where actuation of device and in-
halation needs coordination.
Our study has limitations as well. It is important to mention
that only two sets of measurements were performed limiting
the power of the study. A small number of patients were
included in the study because of the strict inclusion criteria. In
addition, only four inhalers were used, as other devices
FIG. 5. Bland-Altman analysis for Genuair. The X-axis represents the mean of the two measurements for IVCd and PIFd,
while the Y-axis shows the difference of the repeated measurements (first measurement–second measurement). Each dot
represents a person. The dashed line shows the average of the difference for all subjects.





Bias p* 95% LoA CR Bias p* 95% LoA CR
IVCd, L
Ellipta 22 0.068 0.47 -0.772–0.907 – 0.831 30 0.026 0.80 -1.056–1.109 – 1.066
Evohaler 22 0.049 0.44 -0.522–0.620 – 0.566 31 0.048 0.46 -0.643–0.739 – 0.686
Respimat 22 0.040 0.45 -0.432– 0.511 – 0.467 31 -0.075 0.33 -0.900–0.751 – 0.828
Genuair 22 0.294 0.08 -1.156–1.743 – 1.528 20 0.014 0.83 -0.586–0.558 – 0.558
PIFd, L/s
Ellipta 22 -0.049 0.47 -0.651–0.554 – 0.596 30 -0.095 0.10 -0.692–0.502 – 0.616
Evohaler 22 -0.282 0.01 -1.235–0.671 – 1.083 31 -0.085 0.30 -0.961–0.790 – 0.877
Respimat 22 -0.319 0.002 -1.170–0.532 – 1.041 31 -0.128 0.20 -1.198–0.941 – 1.082
Genuair 22 -0.135 0.09 -0.833–0.564 – 0.731 20 -0.063 0.09 -0.367–0.242 – 0.321
*p-Value for one-sample t-test of the bias.
CR, coefficients of repeatability; LoA, Bland-Altman 95% limits of agreement; n, number of subjects.
Significant differences are highlighted in bold.



























































showed distortion in through-device volume and flow mea-
surements in our setup (e.g., Turbuhaler, Breezhaler,
Easyhaler, and HandiHaler). However, future studies
should aim a higher sample size and the inclusion of more
inhalers available on the market. Furthermore, our measure-
ment method should be also tested to aid in the context of
predicting the pulmonary deposition of inhaled drugs.
Conclusions
This study provides new evidence that inhalation pa-
rameters through different inhalers show considerable in-
trasubject and interdevice variability in healthy subjects
and COPD patients. We found that some individuals may
use specific devices more easily and more reliably.
Therefore, to ensure effective inhalation therapy and
symptom relief, it is of great importance to optimize in-
haler technique individually, especially in patients with
COPD independent of disease stability or exacerbation.
Our data indicate that in COPD patients, Respimat and
Genuair are ranked first and second in most patients with
regard to interinhalation variability in IVCd, while Gen-
uair and Ellipta ranked highest in most patients for PIFd.
These observations could potentially provide relevant in-
formation to guide the switch of inhaler devices when
therapy fails in patients with COPD.
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FIG. 6. Repeatability sequence summary for the four inhalers. (A) All-COPD IVCd (n = 20). (B) All-COPD PIFd (n = 20).
(C) Control IVCd (n = 22). (D) Control PIFd (n = 22). By each control subject and patient, a rank number between 1 and 4 was
associated with each inhaler regarding the magnitude of the difference between the two values for PIFd and IVCd, respectively.
Rank 1 was given to the device with the lowest difference between the two inspiratory measurements followed by Rank 2, 3,
and 4. On the figure, rank numbers are shown by four edges of the axes with blue color, and the sum of subjects with a certain
rank is indicated on the axes. COPD, chronic obstructive pulmonary disease. Color images are available online.
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